In this study, case circumstances are presented together with blood concentrations of methoxyacetylfentanyl obtained using a liquid chromatography–tandem mass spectrometric (LC–MS-MS) method alongside urinary metabolite data obtained using liquid chromatography–quadrupole time of flight–mass spectrometry (LC–QTOF–MS).
methoxyacetylfentanyl was obtained from Cayman Chemical (Ann Arbor, MI), and 4-ANPP was obtained from Toronto Research Chemicals (North York, Canada). The internal standard fentanyl-d5 was obtained from Cerilliant (Round Rock, TX). For LC–MS-MS quantification, LC–MS grade acetonitrile, formic acid and methanol were obtained from Fisher Scientific (Gothenburg, Sweden) and ammonium formate from Fluka (Sigma‐Aldrich, Stockholm, Sweden). For sample preparation, gradient grade acetonitrile, methanol and formic acid p.a. (98%) from Merck (Darmstadt, Germany), 95% ethanol from Kemetyl (Haninge, Sweden) and β‐glucuronidase/arylsulfatase (Helix pomatia) from Roche (Mannheim, Germany) were used.
methoxyacetylfentanyl was obtained from Cayman Chemical (Ann Arbor, MI), and 4-ANPP was obtained from Toronto Research Chemicals (North York, Canada). The internal standard fentanyl-d5 was obtained from Cerilliant (Round Rock, TX). For LC–MS-MS quantification, LC–MS grade acetonitrile, formic acid and methanol were obtained from Fisher Scientific (Gothenburg, Sweden) and ammonium formate from Fluka (Sigma‐Aldrich, Stockholm, Sweden). For sample preparation, gradient grade acetonitrile, methanol and formic acid p.a. (98%) from Merck (Darmstadt, Germany), 95% ethanol from Kemetyl (Haninge, Sweden) and β‐glucuronidase/arylsulfatase (Helix pomatia) from Roche (Mannheim, Germany) were used.